



December 16, 2020

Christine H. Monahan
American Oversight
1030 15th Street NW, B255
Washington, DC 20005

RE: FDA FOIA Requests 2020-1977, 2020-4765, 2020-2523;
American Oversight v. HHS et al., Civil No. 20-cv-01063

Dear Ms. Monahan:

This is the final response to the Freedom of Information Act (FOIA) request numbers 2020-1977 and 2020-4765 that are the subject of the Amended Complaint filed in *American Oversight v. HHS et al.*, Civil No. 20-cv-01063, now pending in the U.S. District Court for the District of Columbia. This is also a partial response to FOIA request number 2020-2523.

FDA's Office of the Commissioner sent records to the Department of Health and Human Services and the White House for further review and return to us. The pages under consultation were Bates numbered FDA-OC-2020-1977-000027 through FDA-OC-2020-1977-000057. That consultation has been completed and the records are enclosed.

We have withheld portions of these pages under the exemptions provided in 5 U.S.C. §§ 522(b)(5), and (b)(6) of FOIA, as delineated below:

Exemption (b)(5) permits the withholding of inter-agency or intra-agency communications records which are part of the deliberative process and pre-decisional. Disclosure of such material could inhibit the open and candid expression of opinions and diminish the quality of the decision-making process. The presidential communications privilege (PCP) protects documents solicited and received by the President or his immediate White House advisers who have broad and significant responsibility for investigating and formulating the advice to be given to the President.

Exemption (b)(6) permits the withholding of information which, if released, would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption (b)(6) consists of personal information, such as direct contact information, and conference and passcode numbers, and we have determined that the individuals to whom this information pertains have a substantial privacy interest in withholding it.

Please direct any questions regarding this response to Amy Powell of the U.S. Department of Justice, at (919) 856-4013 or Amy.Powell@usdoj.gov.

Sincerely,

Meredith J. Schlaifer Digitally signed by Meredith J.
Schlaifer -S
-S Date: 2020.12.16 11:21:35 -05'00'

Meredith J. Schlaifer, M.S., J.D.
FOIA Officer, Office of the Commissioner
Division of Freedom of Information
U.S. Food and Drug Administration

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Caliquiri, Laura](#); [Cacomo, Stephanie](#)
Subject: FW: Exclusive: U.S. coronavirus testing threatened by shortage of critical lab materials
Date: Tuesday, March 10, 2020 9:29:20 PM

Hi team FDA-

Sorry for the late email. From my conversations with FDA officials, it seems like (b) (5) DPP



Thanks for all your hard work!!

Devin

Exclusive: U.S. coronavirus testing threatened by shortage of critical lab materials

By David Lim, Brianna Ehley

03/10/2020 06:46 PM EDT

A looming shortage in lab materials is threatening to delay coronavirus test results and cause officials to undercount the number of Americans with the virus.

The slow pace of coronavirus testing has created a major gap in the U.S. public health response. The latest problem involves an inability to prepare samples for testing, creating uncertainties in how long it will take to get results.

CDC Director Robert Redfield told POLITICO on Tuesday that he is not confident that U.S. labs have an adequate stock of the supplies used to extract genetic material from any virus in a patient's sample — a critical step in coronavirus testing.

"The availability of those reagents is obviously being looked at," he said, referring to the chemicals used for preparing samples. "I'm confident of the actual test that we have, but as people begin to operationalize the test, they realize there's other things they need to do the test."

The coronavirus task force convened by the White House is also aware of the shortages, and one official said members are working on it.

The growing scarcity of these "RNA extraction" kits is the latest trouble for U.S. labs, which have struggled to implement widespread coronavirus testing in the seven weeks since the country diagnosed its first case. Epidemiologists and public health officials say that the delayed rollout, caused in part by a botched CDC test, has masked the scope of the U.S. outbreak and hobbled efforts to limit it.

If enough processing kits aren't available, the risk that testing will be disrupted is "huge," said Michael Mina, associate medical director of molecular diagnostics at

Brigham and Women's Hospital in Boston.

“RNA extraction is the first step in being able to perform” a coronavirus test, he said. “If we cannot perform this step, the [coronavirus] test cannot be performed.”

Qiagen, a major supplier of the kits, confirmed that its product is backordered due to “the extraordinary pace” at which the world has increased coronavirus testing over the last few weeks.

Public health labs across the U.S. have tested more than 5,000 people, according to the Trump administration. HHS Secretary Alex Azar told lawmakers on Tuesday that U.S. labs’ capacity could grow to 10,000-20,000 people per day by the end of the week.

“Increased demand for testing has the potential to exhaust supplies needed to perform the test itself,” said Robin Patel, president of the American Society for Microbiology. That would limit the testing capacity of public health, hospital and commercial labs alike, she added.

Complicating the situation, most labs have been running at least two tests per patient — although that could soon change. The [CDC issued interim guidelines on Monday](#) that minimize the number of tests required for a diagnosis. The agency says labs can combine a patient’s nose and throat samples into one test, a move experts say will cut in half the amount of supplies used to test each person.

But Redfield said he doesn’t know how the agency would deal with any scarcity of RNA extraction kits and reagents that arise. “I don’t know the answer to that question,” he said when asked how the CDC would handle such a situation — adding that he is hopeful “there will be mechanisms between multiple manufacturers to correct” it.

Mandy Cohen, North Carolina’s secretary of health, said that a shortage of extraction kits and other chemicals had hampered testing in her state. “Folks were saying, ‘We are sending you the [test] kits,’ and I don’t think they understood at first what exact part of the supply chain we needed,” she said. “We needed extraction kits.”

An FDA spokesperson said that the agency is contacting labs that are testing for the coronavirus “to understand their supply issues and assist where we can.”

The FDA has also approved a change to the CDC diagnostic test that allows labs to switch from Qiagen’s RNA extraction method to another manufactured by Roche, says Denny Russell, who leads the coronavirus response at Washington state’s public health lab. But getting his lab ready to use the Roche method could take a week in part because technicians will need training to use it.

Commercial labs, which have recently started running coronavirus tests, have not experienced any supply shortages, according to a spokesperson for the American Clinical Laboratory Association.

In the meantime, Qiagen has told customers that it may not be able to fill large

standing orders, because it is trying to provide smaller numbers of kits to as many labs as possible, said spokesperson Robert Reitze. The company is ramping up production of RNA extraction kits at manufacturing sites in Hilden, Germany; Barcelona, Spain; and Germantown, Md.

Nancy Cook and Dan Goldberg contributed to this report.

To view online:

<https://protect2.fireeye.com/url?k=58dd2686-04882f95-58dd17b9-0cc47adb5650-dfea81f765650174&u=https://subscriber.politicopro.com/health-care/article/2020/03/exclusive-us-coronavirus-testing-threatened-by-shortage-of-critical-lab-materials-1890423>

You received this POLITICO Pro content because your customized settings include: Alex Azar. To change your alert settings, please go to
<https://protect2.fireeye.com/url?k=b7e7238b-ebb22a98-b7e712b4-0cc47adb5650-571e7506851aeb46&u=https://subscriber.politicopro.com/settings>.

This email alert has been sent for the exclusive use of POLITICO Pro subscriber, judy.stecker@hhs.gov. Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of copyright law and the POLITICO Pro subscription agreement.

Copyright © 2020 by POLITICO LLC. To subscribe to Pro, please go to politicopro.com.

This email was sent to judy.stecker@hhs.gov by:
POLITICO, LLC
1000 Wilson Blvd.
Arlington, VA 22209
USA

From: [O'Malley, Devin M. EOP/OVP](#)
To: [O'Malley, Devin M. EOP/OVP](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Love, Kelly A. EOP/OVP](#)
Subject: Items for Clearance
Date: Saturday, March 14, 2020 5:03:52 PM

Hi everyone-

It's been a busy week, especially the last couple of days. We appreciate everyone's patience, especially (b)(5) DPP. I also want to thank everyone for (b)(5) DPP.

[REDACTED]

On a related note, starting on Monday, the schedule for Task Force related meetings is shifting a bit. This means that Katie and I, and other members of the team, will be harder to get ahold of from the hours of 9:00 am – 11:30 am (instead of 4:00 pm – 6:30 pm). Please consider this when thinking about reviews/clearances. We will also adjust the morning call to a time TBD.

As always, please feel free to call me whenever you have an issue, think something can be done better, or have an idea. We appreciate hearing from you.

Thank you for all you are doing!

Devin

Devin M. O'Malley
202-881-8964

From: [Finnen, April](#)
To: [2019-nCoV FDA IMG JIC Press](#)
Cc: [Lynch, Sarah](#); [2019-nCoV FDA IMG JIC Leadership](#)
Subject: OMA - heads up on VP clearance - FW: NICCL Meeting Call-Out 3.27.2020
Date: Friday, March 27, 2020 2:45:02 PM
Attachments: [image001.png](#)
[image002.png](#)
[ESF15_NICCL_Summary_v2_FINAL_20200327.pdf](#)
[image004.png](#)

From today's NICCL call (full notes attached):

(b)(5) PCP

From: Brubach, April <April.Brubach@fda.hhs.gov>
Sent: Friday, March 27, 2020 1:22 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>
Subject: NICCL Meeting Call-Out 3.27.2020

(b)(5) DPP

April Brubach, 301-512-0780

From: FEMA-ESF15-Coordination <FEMA-ESF15-Coordination@fema.dhs.gov>
Sent: Friday, March 27, 2020 1:07 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>; Clark, Alaina <alaina.clark@cisa.dhs.gov>; Glenn, Amanda <Amanda.Glenn@cisa.dhs.gov>; Palczewski, Andrew (OS) <Andrew.Palczewski@hhs.gov>; ALFONSO-ROYALS, ANGELICA <ANGELICA.ALFONSO-ROYALS@hq.dhs.gov>; Trevino, Anna <anna.trevino@fema.dhs.gov>; Tatem, Anne (OS) <Anne.Tatem@hhs.gov>; CERAOLO, ANTHONY <ANTHONY.CERAOLO@hq.dhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; BOZA-HOLMAN, SOFIA <SOFIA.BOZA-HOLMAN@hq.dhs.gov>; McPherson, Brendan <Brendan.McPherson@hq.dhs.gov>; Glauser, Brittany (OS) <Brittany.Glauser@hhs.gov>; Brown, Lynn <lynn.brown@fema.dhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; Daniels,

Carla L (OS) <Carla.Daniels@hhs.gov>; Castro, Carmen <carmen.castro@fema.dhs.gov>; carol_danko@ios.doi.gov; McCormick, Chad <Chad.McCormick@fema.dhs.gov>; Howlett, Christine <christine.howlett@fema.dhs.gov>; christopher.b.logan.mil@mail.mil; cole_rojewski@ios.doi.gov; Corbin, Susan <Susan.Corbin@hq.dhs.gov>; Coronavirus-Communicators@state.gov; Bradway, Courtney B (OS) <Courtney.Bradway@hhs.gov>; Dracoulis, Danielle <danielle.dracoulis@fema.dhs.gov>; Stellar, Dante <Dante.Stellar@fema.dhs.gov>; Johnston, Darcie (OS) <Darcie.Johnston@hhs.gov>; Passey, David <david.passey@fema.dhs.gov>; Bauer, Debra <Debra.Bauer@fema.dhs.gov>; DMcGaan@doc.gov; Armstrong, Earl <Earl.Armstrong@fema.dhs.gov>; engagement@hhs.gov; eoevent337@cdc.gov; Erickson, Scott <Scott.Erickson@hq.dhs.gov>; Wieczorek, Erin <Erin.Wieczorek@cisa.dhs.gov>; Beck, Gary (OS) <Gary.Beck@hhs.gov>; Genevieve.Giaccardo@bia.gov; Josey, Herbert <Herbert.Josey@cisa.dhs.gov>; HOULTON, TYLER <TYLER.HOULTON@hq.dhs.gov>; isaac.l.taylor.mil@mail.mil; Bass, Jackita D <jackita.bass@cisa.dhs.gov>; Muhammad, Janell M (OS) <Janell.Muhammad@hhs.gov>; Moore, Jeanie <jeanie.moore@cisa.dhs.gov>; Sherman, Jennifer (OS) <Jennifer.Sherman@hhs.gov>; Campora, Jenny W <Jenny.Campora@fema.dhs.gov>; jesus.garcia3@usda.gov; jesus.garcia3@usda.gov; Gountanis, John <John.Gountanis@hq.dhs.gov>; Twomey, John K (OS) <John.Twomey@HHS.GOV>; john_bockmier@ios.doi.gov; Osborne, Jonathan (OS) <Jonathan.Osborne@hhs.gov>; Cox, Jordan (OS) <Jordan.Cox@hhs.gov>; WESTMORELAND, JOSEPH A (OPR) <JOSEPH.A.WESTMORELAND@CBP.DHS.GOV>; Ayala, Juan <juan.ayala@fema.dhs.gov>; Stecker, Judy (OS) <Judy.Stecker@hhs.gov>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Nolan, Kathryn <kathryn.nolan@fema.dhs.gov>; Willcuts, Kathryn <Kathryn.Willcuts@cisa.dhs.gov>; Benacci, Kevin <Kevin.Benacci@cisa.dhs.gov>; Kittrie, Zachary <Zachary.Kittrie@fema.dhs.gov>; Kkilgore@doc.gov; Kneeper@bbg.gov; kpietranton@fbi.gov; Krikava, Richard <Richard.Krikava@fema.dhs.gov>; Kristan Nevins <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Kristina Baum <[\(b\) \(6\)@ostp.eop.gov](mailto:(b) (6)@ostp.eop.gov)>; Kuhns, Daniel (OS) <Daniel.Kuhns@hhs.gov>; Lange, John <John.Lange@hq.dhs.gov>; lashonda.walker@usda.gov; lashonda.walker@usda.gov; Laura Schlapp <laura.a.schlapp.civ@mail.mil>; Laura.J.Brown@faa.gov; Trueman, Laura (OS) <Laura.Trueman@hhs.gov>; Lauren Gorey <lgorey@doc.gov>; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Kotwicki, Lauren (OS) <Lauren.Kotwicki@hhs.gov>; LBGALLAGHER@fbi.gov; leslie.lankster@fns.usda.gov; leslie.lankster@fns.usda.gov; Levine.Carolyn@epa.gov; lhagee@fbi.gov; Litzow, Elizabeth <elizabeth.litzow@fema.dhs.gov>; Ortega, Lorena <lorena.ortega@fema.dhs.gov>; Lori.Irving@dot.gov; Lucero, Mark <Mark.Lucero@fema.dhs.gov>; Lujan, Maria <maria.lujan@fema.dhs.gov>; Lynne.Donahue@usdoj.gov; Macaulay Porter <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; MALIN, STEPHANIE <STEPHANIE.MALIN@cbp.dhs.gov>; mallory bloun <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; RASCHER, MALLORY <MALLORY.RASCHER@hq.dhs.gov>; Mancha, Patricia <Patricia.Mancha@fema.dhs.gov>; Marc Short <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; Marc.Raimondi@usdoj.gov; Margaret.Schaefer@dhs.gov; mark hinkle <mark.hinkle@ssa.gov>; Mark Mchale <mark.mchale@gsa.gov>; Mark.Ballesteros@va.gov; Weber, Mark (OS) <Mark.Weber@hhs.gov>; Mary.A.Brandenberger@usdoj.gov; Mary.E.Markos@usace.army.mil; Mary.E.Markos@usace.army.mil; Matt Schuck <Matthew.J.Schuck@hud.gov>; Matt Sheehey <msheehey@peacecorps.gov>; Matthew Lahr <matthew.lahr@dni.gov>; Matthew.Borgia@noaa.gov; Matthew.Burrell@gsa.gov; Maura.Beard@nctc.gov; McBride, Scott A LCDR <Scott.A.McBride@uscg.mil>; McCachrenC@state.gov; McCulloch, Robert <robert.mcculloch@fema.dhs.gov>; MCKENZIE MELISSA M <melissa.mckenzie@ussf.dhs.gov>; MCMURRAY JULIA <Julia.Dagostino@ussf.dhs.gov>; McNeil, Elizabeth <elizabeth.mcneil@fema.dhs.gov>; Meddie.Brown@gsa.gov; Media Inquiry <MediaInquiry@HQ.DHS.GOV>; media@ucia.gov; mediarelations@fcc.gov; Cardin, Megan <Megan.Cardin@fda.hhs.gov>; McSeveney, Megan <Megan.McSeveney@fda.hhs.gov>; Megan.O'Kane@dhs.gov; Meghan Burris <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; [Meghan.Rodgers@oc.usda.gov](mailto: Meghan.Rodgers@oc.usda.gov); Wilkins, Melissa <melissa.wilkins@fema.dhs.gov>; Good-Cohn, Meredith (CMS) <Meredith.Good-Cohn@cms.hhs.gov>; Merry Lin <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; MGuarracino@supremecourt.gov; Heck, Mia (OS) <Mia.Heck@hhs.gov>; Michael Abboud <abboudmc@state.gov>; Michael Dubray <dubraymr@state.gov>; Pratt, Michael (OS) <Michael.Pratt@hhs.gov>; Dailey, Michael A <Michael.A.Dailey@cisa.dhs.gov>; Michael.Birmingham@dni.gov; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Michael.P.Knight@usdoj.gov; Michael.w.Dendas@hud.gov; Michawn Rich <Michawn.rich@usda.gov>; Michawn.Rich@osec.usda.gov; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Michelle Dawi <[\(b\) \(6\)@ho.eop.gov](mailto:(b) (6)@ho.eop.gov)>; Michelle.Coghill@usdoj.gov; Michelle.Hindmarch@hq.doe.gov; Michelle.laver@nnsa.doe.gov; Midgett, Amy LT <Amy.Midgett@uscg.mil>; Mike Korbey <mike.korbey@ssa.gov>; Mike.Illenberg@oc.usda.gov; MILHOAN CATHERINE L <catherine.milhoan@ussf.dhs.gov>; Miller, Bennett <Bennett.Miller@hq.dhs.gov>; Mina, Peter <Peter.Mina@hq.dhs.gov>; mira.lezell@dot.gov; Mizelle, Chad <Chad.Mizelle@hq.dhs.gov>; Harris, Missy J (NIH) <mjharris@mail.nih.gov>; MNLowry@fbi.gov; Molly Block <block.molly@epa.gov>; molly.meiners@treasury.gov; Morgan Bedan <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Morgan Ortagus <OrtagusMD@state.gov>; msgaine@cybercom.mil; Msiegel@doc.gov; msimms2@peacecorps.gov; Nalepa, Jessica <jessica.nalepa@fema.dhs.gov>; nancy gonzalez <nancy.gonzalez@ssa.gov>; NASON MICHAEL C <michael.nason@ussf.dhs.gov>; Best, Natalia <Natalia.Best@hq.dhs.gov>; Natalie Hurst <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; NationalJIC@dhs.gov; Lemar, Naweed (OS) <Naweed.Lemar@hhs.gov>; nctcpao@nctc.gov; Ndidi.Mojay@va.gov; Nelson, Jason <Jason.Nelson2@fema.dhs.gov>; NewsMedia@nps.gov; ng.ncr.ngb-arng.mbx.ngbjccpa@mail.mil; Pottebaum, Nicholas (who.eop.gov) <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Nicholas_Goodwin@ios.doi.gov; nicole tiggemann <nicole.tiggemann@ssa.gov>; nicole.peckumn@dc.gov; Nicole.Schwegman@pacom.mil; nigel.holderby@redcross.org; Thomas, Nkosi <Nkosi.Thomas@hq.dhs.gov>; nlpitto@nsa.gov; n-nc.peterson-n-ncspecialstaff.mbx.usnorthcom-pa-omb@mail.mil; NOC SWO Restricted <NOC.SWO.Restricted@hq.dhs.gov>; NOC.NDD@hq.dhs.gov; Noelker, Tim <tnoelker@cns.gov>; npo@fbi.gov; NSAmedia@nsa.gov; Imhoff, Olivia (who.eop.gov) <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Olshanski, Thomas <Thomas.Olshanski@fema.dhs.gov>; opa@hq.dhs.gov; osd.pa.dutyofficer@mail.mil; Overton, Kristina <kristina.overton@fema.dhs.gov>; owen.morgan@dot.gov; pacom.i0pac.duty.pao@navy.mil; pacrisisresponse@state.gov; Pallas, Charissa M <Charissa.M.Pallas@ice.dhs.gov>; pamela Pennington <pamela.pennington@gsa.gov>; Pamela.s.kunze@mail.mil; Conrad, Patricia L (NIH) <conradpa@niaid.nih.gov>; El-

Hinnawy, Patricia <Patricia.ElHinnawy@fda.hhs.gov>; Brennan, Patrick (OS) <Patrick.Brennan@hhs.gov>; Patrick.h.cordova@mail.mil; Paul.F.Smith@usps.gov; Formoso, Paula (OS) <Paula.Formoso@hhs.gov>; Gutierrez, Paula <paula.gutierrez@fema.dhs.gov>; Paulk-Buchanan, Crystal <crystal.paulk-buchanan@fema.dhs.gov>; PAYNE, LAWRENCE R <LAWRENCE.R.PAYNE@cbp.dhs.gov>; Payton, Crystal <Crystal.Payton@fema.dhs.gov>; Peter Hoffman <(b) (6) @who.eop.gov>; Peter Carr <Peter.Carr@usdoj.gov>; Cassell, Peter <Peter.Cassell@fda.hhs.gov>; Peter Knudson <Peter.Knudson@ntsb.gov>; Peter Krug <Peter.krug@uspto.gov>; Peterson, Mark J <Mark.Peterson2@fema.dhs.gov>; Peterson1W@state.gov; Phillips, James M <James.M.Phillips@hq.dhs.gov>; Phillips, Kimberly <Kimberly.Phillips@fema.dhs.gov>; PicardVM@state.gov; Pierce, Bradley <bradly.pierce@fema.dhs.gov>; Pinkham, Dennis <Dennis.Pinkham@fema.dhs.gov>; pio@supremecourt.gov; PKaplan@ftc.gov; Platt, Michael E CAPT <Michael.E.Platt@uscg.mil>; Pooja Jhunjunwala <pjhunjunwala@usaid.gov>; press.office@ssa.gov; PressOffice@dot.gov; Privatesector@hq.dhs.gov; Public.Affairs@socom.mil; publicaffairs.pacom@navy.mil; publicaffairs@doc.gov; Purdy, Adoratia <adoratia.purdy@fema.dhs.gov>; qig3@cdc.gov <qig3@cdc.gov>; Quinn, Cameron <Cameron.Quinn@hq.dhs.gov>; Rachel Semmel <(b) (6) @omb.eop.gov>; Nutter, Rachel <rachel.nutter@fema.dhs.gov>; rachel_levin@ios.doi.gov; Raini.W.Brunson@usace.army.mil; Ramsay, Cindy <cindy.ramsay@fema.dhs.gov>; Semke, Rand <Rand.Semke@hq.dhs.gov>; randy.ready@pacom.mil; Raymond, Joe W CAPT <Michael.W.Raymond@uscg.mil>; rcparker@usaid.gov; Readinger, Jeff <Jeff.Readinger@HQ.DHS.GOV>; Rebecca Miller <rebecca.miller@treasury.gov>; Armstrong, Rebekah W (OS) <Rebekah.Armstrong@hhs.gov>; Reinhold, Kent R CDR <Kent.R.Reinhold@uscg.mil>; Renee Hudson <(b) (6) @ho.eop.gov>; Richard.a.crusan.civ@mail.mil; Richardson, Yasamie <yasamie.richardson@fema.dhs.gov>; Richardson.RobinH@epa.gov; Rideaux.Chantra.d@dol.gov; Rob <robbinse@state.gov>; Robert Bozzuto <bozzuto.robert.F@DOL.gov>; robert.l.perino.mil@mail.mil; (b) (6) @omb.eop.gov; Robert.Nadeau@noaa.gov; robert.sperling@hq.dhs.gov; Robert.Tuttle@hq.doe.gov; Robinson1A2@state.gov; Rochelle.Cohen@fcc.gov; Rodriguez.Juan@dol.gov; ronald.mclendon6.civ@mail.mil; Rossie, Camilla <Camilla.Rossie@fema.dhs.gov>; RRMuhammad@fbi.gov; Russell, Anthony L CAPT <Anthony.L.Russell@uscg.mil>; Russell.Oneill@gsa.gov; Russell.Newell@ios.doi.gov; Clemens, Ruth <Ruth.Clemens@cisa.dhs.gov>; Ryan Essman <ressman@usaid.gov>; Ryan Kaldahl <kaldahlrm@state.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Ryan, Charles <charles.ryan@fema.dhs.gov>; Samantha Schwab <(b) (6) @ovp.eop.gov>; samuel.r.souvannason.ctr@mail.mil; Samuels, Jessie <Jessie.Samuels@fema.dhs.gov>; SAPP, STEPHEN <STEPHEN.SAPP@cbp.dhs.gov>; (b) (6) @who.eop.gov; Sara.L.Eguren@irs.gov; Sendek, Sara <Sara.Sendek@cisa.dhs.gov>; Arbes, Sarah C (OS) <Sarah.Arbes@hhs.gov>; sarah.case-herron@dc.gov; Sauerhage.Maggie@epa.gov; SSCI_Press@state.gov; Scott Calhoun <Scott.calhoun@dot.gov>; Blakeman, Scott (OS) <Scott.Blakeman@hhs.gov>; Scott.Smullen@noaa.gov; sean.mcmaster@dot.gov; sean.poole@dot.gov; seth.unger@treasury.gov; sfontaine@usaid.gov; Shaylyn.Hynes@hq.doe.gov; Shefveland, Alan <Alan.Shefveland@fletc.dhs.gov>; Sheila.Johnston@pacom.mil; SHORT, CHERIE <CHERIE.SHORT@hq.dhs.gov>; Myrie, Simone (OS) <Simone.Myrie@hhs.gov>; Simons, Michael <michael.simons@tsa.dhs.gov>; Siwarfield@cns.gov; SMITH, LAUREL <LAUREL.SMITH@CBP.DHS.GOV>; Smith, Yvonne <yvonne.smith@fema.dhs.gov>; Snyder, Elizabeth <Elizabeth.Snyder@fema.dhs.gov>; Socialmedia@faa.gov; southcom.miami.sc-cc.list.cmd-public-affairs@mail.mil; Sscott@cns.gov; Sshero@fbi.gov; Ecoffey, Stacey (OS) <stacey.ecoffey@hhs.gov>; Palosky, Stacey (OS) <Stacey.Palosky@hhs.gov>; StanfordAD@state.gov; StarrKL@state.gov; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; Stephanie Grisham <(b) (6) @who.eop.gov>; Stephanie.c.fila@hud.gov; Zumwalt, Steven <Steven.Zumwalt@fema.dhs.gov>; Stmckee@fbi.gov; Stoneking, Daniel <Daniel.Stoneking@fema.dhs.gov>; Streeter, Ryan <Ryan.Streeter@hq.dhs.gov>; Strouse, Philip <Philip.Strouse@fema.dhs.gov>; Carlson, Sue <Sue.Carlson@fema.dhs.gov>; Sunset.r.Belinsky.mil@mail.mil; Susan Varga <(b) (6) @who.eop.gov>; Susan.b.miller@nctc.gov; Susanna.Marking-Stockl@uscg.gov; Sellman, Suzanne (OS) <Suzanne.Sellman@hhs.gov>; SWIFT, HEATHER <HEATHER.SWIFT@hq.dhs.gov>; Tagliento, Marc <Marc.Tagliento@fema.dhs.gov>; Broido, Tara (OS) <Tara.Broido@hhs.gov>; Bradley, Tasha (OS) <Tasha.Bradley@hhs.gov>; taylor.l.weeks@nasa.gov; TdJagerson@fbi.gov; Terrence.Hayes@va.gov; Terrence.Sutherland@sba.gov; t-hannen3@cranfordnj.org; Corry, Thomas (CMS) <Thomas.Corry@cms.hhs.gov>; Thompson, Christa <Christa.Thompson@fletc.dhs.gov>; Foster, Timothy (OS) <Timothy.Foster@hhs.gov>; timothy_williams@ios.doi.gov; (b) (6) @who.eop.gov; Vitek, Traci (OS) <Traci.Vitek@hhs.gov>; tracy.a.ogrady-walsh.civ@mail.mil; Travis.Edwards@ice.dhs.gov; trhanna@nsa.gov; Troye, Olivia <(b) (6) @nsc.eop.gov>; Trupo.Michael@dol.gov; TUTONI VINCENT A <vincent.tutoni@usss.dhs.gov>; Urbani, Adrien <adrien.urbani@fema.dhs.gov>; usagovemergency@gsa.gov; USCIS EXA NICCL Group <USCISEXANICCLGroup@uscis.dhs.gov>; Venture, Veronica <Veronica.Venture@HQ.DHS.GOV>; Vermette, Joseph <Joseph.Vermette@fema.dhs.gov>; veronica.davison.civ@mail.mil; Walsh, Brett <brett.walsh@fema.dhs.gov>; Ward, Erin <Erin.Ward@fema.dhs.gov>; Web Publishing <WebPublishing@HQ.DHS.GOV>; Wehagen, Robby <robbie.wehagen@fema.dhs.gov>; Crozer, William (who.eop.gov) <(b) (6) @who.eop.gov>; Wilson, Thomas <thomas.wilson2@fema.dhs.gov>; Witmer, Wade <Wade.Witmer@fema.dhs.gov>

Subject: NICCL Summary 3.27.2020

Good afternoon,

Attached is the NICCL Summary for today's call. Thank you for your agency's participation.

Best,

Alexa Fortuna

Emergency Management Specialist | FEMA ESF 15 Coordination | Office of External Affairs

Mobile: (b) (6)

FEMA-ESF15-Coordination@fema.dhs.gov

Federal Emergency Management Agency
[fema.gov](https://www.fema.gov)

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Rom, Colin](#); [Shah, Anand](#); [Cacomo, Stephanie](#)
Cc: [Murphy, Ryan \(OS\)](#); [Miller, Katie R. EOP/OVP](#)
Subject: Project
Date: Saturday, March 21, 2020 2:50:46 PM

Hey guys-

(b)(5) - DPP

Dr. Hahn mentioned the name of a woman at FDA that would walk the reporter through some of the technical aspects, but I forget her name. Could you get this done tomorrow for online (and the Monday print)? (b)(5) - DPP

Thanks!

Devin

Devin M. O'Malley

(b) (6)

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Caccommo, Stephanie](#); [Hall, Bill \(OS\)](#); [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#)
Cc: [Murphy, Ryan \(OS\)](#); [Oakley, Caitlin B \(OS\)](#); [McKeogh, Katherine \(OS\)](#); [Caliguiri, Laura](#); [Felberbaum, Michael](#)
Subject: RE: FDA release on chloroquine
Date: Thursday, March 19, 2020 2:09:29 PM
Attachments: [image001.png](#)

(b)(5) - DPP

From: Caccommo, Stephanie <Stephanie.Caccommo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 2:01 PM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b) (6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b)(5) - DPP

Stephanie Caccommo

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: [301.348.1956](#)
Cell: [240.762.8873](#)
stephanie.caccommo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <(b) (6) @ovp.eop.gov>
Date: March 19, 2020 at 1:53:15 PM EDT
To: Caccommo, Stephanie <Stephanie.Caccommo@fda.hhs.gov>; Hall, Bill (OS) (b) (6) @hhs.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b) (6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael

<Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b)(5) - DPP

From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 1:37 PM
To: O'Malley, Devin M. EOP/OVP (b)(6) @ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP (b)(6) @ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b)(6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

Will do. (b)(5) can we issue?

Stephanie Caccamo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccamo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP (b)(6) @ovp.eop.gov>
Sent: Thursday, March 19, 2020 1:35 PM
To: Hall, Bill (OS) (b)(6) @hhs.gov>; Miller, Katie R. EOP/OVP (b)(6) @ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b)(6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b)(5) - DPP

From: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Sent: Thursday, March 19, 2020 1:24 PM
To: O'Malley, Devin M. EOP/OVP (b)(6) @ovp.eop.gov>; Miller, Katie R. EOP/OVP (b)(6) @ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b)(6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B. (OS/ASPA)

<Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>;
Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC)
<Stephanie.Caccomo@fda.hhs.gov>

Subject: FDA release on chloroquine

All...FDA is ready to issue this. Please let us know if we have the green light. Bill

William Hall

Deputy Assistant Secretary for Public Affairs (Public Health)
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health & Human Services
Washington, DC
Direct: 202-690-6344
Mobile: 202-823-2008
Email: bill.hall@hhs.gov
>>>www.hhs.gov<<<



From: [O'Malley, Devin M. EOP/OVP](#)
To: [Caccommo, Stephanie](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Manchester, Brittney](#); [Felberbaum, Michael](#); [Caliguiri, Laura](#)
Subject: Re: flag--media response re: n95 sterilization
Date: Sunday, March 29, 2020 1:58:40 PM

(b) (5) - DPP

Sent from my iPhone

On Mar 29, 2020, at 1:34 PM, Caccommo, Stephanie
<Stephanie.Caccommo@fda.hhs.gov> wrote:

Hi folks—

Flagging for you (b) (5) - DPP

(b) (5) - DPP

Response:

(b) (5) - DPP

Stephanie Caccommo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: [O'Malley, Devin M. EOP/OVP](#)
To: [McGowan, Robert K \(CDC\)](#)
Cc: [McGuffee, Tyler A. EOP/OVP](#); [Hahn, Stephen](#); [Birx, Deborah L. EOP/NSC](#); [Fauci, Anthony S \(NIH\)](#); [Redfield, Robert R \(CDC\)](#); [Miller, Katie R. EOP/OVP](#); [Rom, Colin](#); [Lane, Henry C \(NIH\)](#); [Lenihan, Keagan](#); [Cacomo, Stephanie](#); [Caliquiri, Laura \(OS\)](#); [Galatas, Kate \(CDC\)](#); [Bonds, Michelle E \(CDC\)](#); [Murphy, Ryan \(OS\)](#)
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document
Date: Saturday, March 21, 2020 3:27:44 PM

Adding the appropriate hhs Comms components to make sure they follow up with policy offices to start promoting this

Sent from my iPhone

On Mar 21, 2020, at 2:44 PM, McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov> wrote:

Thank you. We will post it shortly.

Get [Outlook for iOS](#)

From: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>
Sent: Saturday, March 21, 2020 2:43:47 PM
To: McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; McGuffee, Tyler A. EOP/OVP (b) (6) @ovp.eop.gov>; Hahn, Stephen (b) (6) @fda.hhs.gov>; Birx, Deborah L. EOP/NSC (b) (6) @nsc.eop.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) @niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) @ovp.eop.gov>
Cc: Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>; Lane, Cliff (NIH/NIAID) [E] <CLANE@niaid.nih.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

My understanding is that our approval was the final outstanding approval, so if that's correct then yes.

From: McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>
Sent: Saturday, March 21, 2020 2:42 PM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>; McGuffee, Tyler A. EOP/OVP (b) (6) @ovp.eop.gov>; Hahn, Stephen (b) (6) @fda.hhs.gov>; Birx, Deborah L. EOP/NSC (b) (6) @nsc.eop.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) @niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) @ovp.eop.gov>
Cc: Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>; Lane, Cliff (NIH/NIAID) [E] <CLANE@niaid.nih.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Is the CDC cleared to post this on our website?

Get [Outlook for iOS](#)

From: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>
Sent: Saturday, March 21, 2020 2:38:18 PM
To: McGuffee, Tyler A. EOP/OVP (b) (6) ovp.eop.gov>; Hahn, Stephen (b) (6) fda.hhs.gov>; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov>
Cc: Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov>; Lane, Cliff (NIH/NIAID) [E] <CLANE@niaid.nih.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Good. Just want to make sure that the appropriate comms teams know that we want to see the content that promotes this before it goes out. Thanks!

From: McGuffee, Tyler A. EOP/OVP (b) (6) ovp.eop.gov>
Sent: Saturday, March 21, 2020 2:26 PM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>; Hahn, Stephen (b) (6) fda.hhs.gov>; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov>; Fauci, Anthony S (NIH) (b) (6) niaid.nih.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Message from Dr. Stephen Hahn to all:

Attached is the FINAL v9. Dr. Hahn and Devin O'Malley just met in person and made the following changes:

(b) (5) - DPP

Pushing this back to OVP Comms for final affirmative clearance. Please advise when approved by OVP Comms we are ready for OVP comms to coordinate with Dr. Redfield, CDC communications and others on publication.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: (202) 881-8195 [no text]

From: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov
Sent: Saturday, March 21, 2020 1:59 PM
To: McGuffee, Tyler A. EOP/OVP (b) (6) ovp.eop.gov; Hahn, Stephen (b) (6) fda.hhs.gov; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov; Fauci, Anthony S (NIH) (b) (6) niaid.nih.gov; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Some thoughts attached (b) (5) - DPP
[REDACTED]

From: McGuffee, Tyler A. EOP/OVP (b) (6) ovp.eop.gov
Sent: Saturday, March 21, 2020 1:14 PM
To: Hahn, Stephen (b) (6) fda.hhs.gov; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov; Fauci, Anthony S (NIH) (b) (6) niaid.nih.gov; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ovp.eop.gov; O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Message from Dr. Stephen Hahn to OVP Comms:

Attached is the FINAL information for clinicians regarding treatment of COVID-19 patients. This has been reviewed and approved by the principals in the "To:" line. When approved by OVP Comms we are ready for you to coordinate with Dr. Redfield, CDC communications and others on publication.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: (202) 881-8195 [no text]

From: Hahn, Stephen <(b) (6)@fda.hhs.gov>
Sent: Saturday, March 21, 2020 12:48 PM
To: Birx, Deborah L. EOP/NSC <(b) (6)@nsc.eop.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; McGuffee, Tyler A. EOP/OVP <(b) (6)@ovp.eop.gov>; Fauci, Anthony S (NIH) <(b) (6)@niaid.nih.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

(b)(5) - DPP

From: Birx, Deborah L. EOP/NSC <(b) (6)@nsc.eop.gov>
Date: March 21, 2020 at 12:40:16 PM EDT
To: Lane, Henry C (NIH) <clane@niaid.nih.gov>, McGuffee, Tyler A. EOP/OVP <(b) (6)@ovp.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)@niaid.nih.gov>, Hahn, Stephen <(b) (6)@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

(b) (5) - DPP

(b) (5) - DPP deb

From: "Lane, Cliff (NIH/NIAID) [E]" <clane@niaid.nih.gov>
Date: Saturday, March 21, 2020 at 12:31 PM
To: "McGuffee, Tyler A. EOP/OVP" <(b) (6)@ovp.eop.gov>, "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)@niaid.nih.gov>, "Hahn, Stephen" <(b) (6)@fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <(b) (6)@nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>
Cc: "Rom, Colin (FDA/OC)" <Colin.Rom@fda.hhs.gov>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" <omc2@cdc.gov>

Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

I realize I am on the cc line, however I have three comments and have tracked suggestions:

(b) (5) - DPP

Cliff Lane

From: "McGuffee, Tyler A. EOP/OVP" <(b) (6) ovp.eop.gov>
Date: Saturday, March 21, 2020 at 11:33 AM
To: Anthony Fauci <(b) (6) niaid.nih.gov>, "Hahn, Stephen" <(b) (6) fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <(b) (6) nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>
Cc: "Lane, Cliff (NIH/NIAID) [E]" <clane@niaid.nih.gov>, "Rom, Colin (FDA/OC)" <Colin.Rom@fda.hhs.gov>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" <omc2@cdc.gov>
Subject: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Per Dr. Hahn, V6 attached for FINAL approval. Please REPLY ALL with affirmative clearance.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: (202) 881-8195 [no text]

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6) niaid.nih.gov>
Sent: Friday, March 20, 2020 7:47 PM
To: Hahn, Stephen <(b) (6) fda.hhs.gov>
Cc: Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Birx, Deborah L. EOP/NSC <(b) (6) nsc.eop.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; McGuffee, Tyler A. EOP/OVP <(b) (6) ovp.eop.gov>; Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>
Subject: RE: Treatment Document

Sounds good to me.

Thanks,

Tony

From: Hahn, Stephen <(b) (6)fda.hhs.gov>

Sent: Friday, March 20, 2020 7:36 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>

Cc: Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Birx, Deborah L. EOP/NSC <(b) (6)nsc.eop.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; (b) (6)ovp.eop.gov; Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>

Subject: Re: Treatment Document

Tony,

Looks like we (b) (5) - DPP. The group wants to make some more edits and then send out this evening for review. We would like to meet up prior to or after the task force meeting tomorrow. Sound OK?

Steve

Sent from my iPad

On Mar 20, 2020, at 7:06 PM, Hahn, Stephen <(b) (6)fda.hhs.gov> wrote:

I have a couple of comments

(b) (5) - DPP

I'll await for other comments.

Thanks

Steve

Sent from my iPad

On Mar 20, 2020, at 6:45 PM, Fauci, Anthony (NIH/NIAID) [E]

<(b) (6)niaid.nih.gov> wrote:

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. First, I stated what the purpose of the document is in the introduction. I have removed granular material that I do not feel contributes to our purpose. In addition, I have not checked out the references with the statements that were made. I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: (b) (6) niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<dbInformation for Clinicians on COVID-19 Therapies31hcl -
with Fauci and Lane tracked changes showing.docx>
<dbInformation for Clinicians on COVID-19 Therapies31hcl -
with Fauci and Lane tracked Clean copy.docx>

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Galatas, Kate \(CDC\)](#); [Cacomo, Stephanie](#); [Caliguri, Laura](#); [Murphy, Ryan \(OS\)](#)
Cc: [Hall, Bill \(OS\)](#); [Bonds, Michelle E \(CDC\)](#); [Oakley, Caitlin B \(OS\)](#); [Miller, Katie R. EOP/OVP](#); [Love, Kelly A. EOP/OVP](#)
Subject: RE: Releases
Date: Friday, March 13, 2020 7:49:05 AM

Someone had mentioned that (b) (5) - DPP. No worries if not.

From: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>
Sent: Friday, March 13, 2020 7:48 AM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>; Cacomo, Stephanie (FDA/OC) <Stephanie.Cacomo@fda.hhs.gov>; Caliguri, Laura (FDA/OC) <Laura.Caliguri@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Miller, Katie R. EOP/OVP <(b) (6) ovp.eop.gov>; Love, Kelly A. EOP/OVP (b) (6) ovp.eop.gov>
Subject: Re: Releases

We are having a telebriefing at 1pm today — (b) (5) - DPP. Undoubtedly we will be asked about this today and will be ready to respond on the telebriefing.

Take care,
Kate

Get [Outlook for iOS](#)

From: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>
Sent: Friday, March 13, 2020 7:37:44 AM
To: Cacomo, Stephanie (FDA/OC) <Stephanie.Cacomo@fda.hhs.gov>; Caliguri, Laura (FDA/OC) <Laura.Caliguri@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Miller, Katie R. EOP/OVP <(b) (6) ovp.eop.gov>; Love, Kelly A. EOP/OVP <(b) (6) ovp.eop.gov>
Subject: RE: Releases

Is anyone from the CDC available to provide an update on their end? I can wait to send our release if they have something to include.

From: Cacomo, Stephanie <Stephanie.Cacomo@fda.hhs.gov>
Sent: Friday, March 13, 2020 6:34 AM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>; Caliguri, Laura <Laura.Caliguri@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; Miller, Katie R. EOP/OVP <(b) (6) ovp.eop.gov>; Love, Kelly A. EOP/OVP <(b) (6) ovp.eop.gov>

Subject: RE: Releases

Noted. Will push soon

Stephanie Caccamo

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: [301.348.1956](tel:3013481956)
Cell: [240.762.8873](tel:2407628873)
stephanie.caccamo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>

Date: March 13, 2020 at 3:59:21 AM EDT

To: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>, Caliguiri, Laura
<Laura.Caliguiri@fda.hhs.gov>, Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>

Cc: Hall, Bill (OS) <bill.hall@hhs.gov>, Galatas, Kate (CDC) <kkg2@cdc.gov>, Bonds,
Michelle E (CDC) <meb0@cdc.gov>, Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>,
Miller, Katie R. EOP/OVP <(b) (6) ovp.eop.gov>, Love, Kelly A. EOP/OVP
<(b) (6) ovp.eop.gov>

Subject: RE: Releases

Importance: High

Hi all-

Here is the plan:

(b) (5) - DPP


Thanks for your coordination on this; I think it will prove to be more effective.

Devin

(b) (5) - DPP

(b) (5) - DPP

(b) (5) - DPP



From: Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>

Sent: Friday, March 13, 2020 12:06 AM

To: O'Malley, Devin M. EOP/OVP <(b) (6)@ovp.eop.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>

Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>

Subject: RE: Releases

Hi Devin—

Attaching our draft release. These actions happened this evening (within the last hour), so they can be discussed in AM TV programs. Please feel free to call if you need any walk through on any of this.

Stephanie Caccomo

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <(b) (6)@ovp.eop.gov>

Sent: Thursday, March 12, 2020 10:56 PM

To: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>

Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>

Subject: RE: Releases

Checking in on where folks are at with their releases.

(b) (5) - DPP

From: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>

Sent: Thursday, March 12, 2020 8:32 PM

To: O'Malley, Devin M. EOP/OVP <(b) (6)@ovp.eop.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>

Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>

Subject: RE: Releases

Here is where we are: We are buttoning up on our end, going through our clearance, (b) (5) - DPP

[REDACTED]

From: O'Malley, Devin M. EOP/OVP <(b) (6)@ovp.eop.gov>

Sent: Thursday, March 12, 2020 8:27 PM

To: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Subject: RE: Releases

Thank you. Put NIH on by accident. Taking them off now.

From: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Sent: Thursday, March 12, 2020 8:25 PM
To: O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov>
Cc: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>
Subject: Re: Releases

+ Stephanie and Laura w/ FDA

On Mar 12, 2020, at 8:20 PM, O'Malley, Devin M. EOP/OVP (b) (6) @ovp.eop.gov> wrote:

Hi CDC and FDA-

I've heard from each of you separately that you will have testing-related press releases tomorrow.

Can you let me know how the drafting of materials is going? (b) (5) - DPP

[REDACTED]

Thanks!

Devin

Devin M. O'Malley
202-881-8964

From: [O'Malley, Devin M. EOP/OVP](#)
To: [O'Malley, Devin M. EOP/OVP](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Love, Kelly A. EOP/OVP](#)
Subject: Upcoming Items
Date: Saturday, March 14, 2020 6:16:24 PM

Hi all-

You are receiving this email because you have a principal that is on the Task Force or frequently attends its meetings. (b) (5) - DPP



As you may know, we are working on meetings with nurses, physicians, and the tourism industry, so having a sense of what you all may be planning could help us build out a more robust communications plan around those meetings.

Thanks!

Devin

Devin M. O'Malley
202-881-8964

From: [Murphy, Ryan \(OS/ASPA\)](#)
To: [Lemar, Naweed \(OS\)](#); [Robinson, Michael J \(OS\)](#); [Myrie, Simone \(OS\)](#); [Bradley, Tasha \(OS\)](#); [Formoso, Paula \(OS\)](#); [Daniels, Carla L \(OS\)](#); [Felberbaum, Michael](#); [Cacomo, Stephanie](#); [Block, Molly](#); [Galatas, Kate \(CDC\)](#); [Bonds, Michelle E \(CDC\)](#); [Oury, Rachael \(CDC\)](#); [Billet, Courtney R \(NIH\)](#); [Routh, Jennifer M \(NIH\)](#); [Burklow, John T \(NIH\)](#); [Myles, Renate H \(NIH\)](#); [Michael, Gretchen \(OS\)](#); [Kane, Elleen \(OS\)](#); [Danko, Carol \(OS\)](#); [Heck, Mia \(OS\)](#); [Broido, Tara \(OS\)](#); [Sherman, Jennifer \(OS\)](#)
Cc: [Blakeman, Scott \(OS\)](#); [Brennan, Patrick \(OS\)](#); [Caputo, Michael R \(OS\)](#); [Foster, Timothy \(OS\)](#); [Hall, Bill \(OS\)](#); [McKeogh, Katherine \(OS\)](#); [Oakley, Caitlin B \(OS\)](#); [Pratt, Michael \(OS\)](#); [Traverse, Brad \(OS\)](#); [Weber, Mark \(OS\)](#)
Subject: UPDATED: for clearances
Date: Friday, May 15, 2020 3:32:24 PM

Hey Folks – I hope everyone is having a good Friday afternoon. I wanted to send a quick update on the process here. Below are updated lists of WH and OVP folks who need to be on the clearance emails you send up to the WH/OVP. Also, please make sure that you receive affirmative WH approval in addition to OVP approval before proceeding.

Appreciate everyone's assistance and great work. Please let me know if you've any questions.

Thanks,

Ryan

For material and print interview clearances –

Devin O'Malley [\(b\) \(6\) @ovp.eop.gov](#)
Katie Miller [\(b\) \(6\) @ovp.eop.gov](#)
Hannah MacInnis [\(b\) \(6\) @ovp.eop.gov](#)
Alyssa Farah [\(b\) \(6\) @who.eop.gov](#)
Kayleigh Gilmartin [\(b\) \(6\) @who.eop.gov](#)
Hogan Gidley [\(b\) \(6\) @who.eop.gov](#)
Brittany Yanick [\(b\) \(6\) @who.eop.gov](#)
Tori Syrek [\(b\) \(6\) @who.eop.gov](#)
Judd Deere [\(b\) \(6\) @who.eop.gov](#)

For broadcast interview clearances –

Devin O'Malley
Katie Miller
Hannah MacInnis
Alyssa Farah
Kayleigh Gilmartin

Hogan Gidley

Brittany Yanick

Tori Syrek

Judd Deere

Alexa Henning (b) (6) @who.eop.gov

Roma Daravi (b) (6) @who.eop.gov

John Hortsman (b) (6) @who.eop.gov

From: Murphy, Ryan (OS/ASPA)

Sent: Monday, May 11, 2020 3:21 PM

To: Lemar, Naweed (OS/ASPA) <Naweed.Lemar@hhs.gov>; Michael Robinson (michael.robinson@hhs.gov) <michael.robinson@hhs.gov>; Simone Myrie (Simone.Myrie@hhs.gov) <Simone.Myrie@hhs.gov>; Bradley, Tasha (OS/ASPA) <Tasha.Bradley@hhs.gov>; Formoso, Paula (HHS/ASPA) <Paula.Formoso@hhs.gov>; Daniels, Carla (HHS/ASPA) <Carla.Daniels@hhs.gov>; Felberbaum, Michael (FDA/OC) <Michael.Felberbaum@fda.hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Molly Block (Molly.Block@fda.hhs.gov) <Molly.Block@fda.hhs.gov>; Kate Galatas (CDC/OD/OADC) (kkg2@cdc.gov) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oury, Rachael (CDC/OD) <QKC3@cdc.gov>; Courtney (NIH/NIAID) Billet [E] (billetc@niaid.nih.gov) <billetc@niaid.nih.gov>; Jennifer (NIH/NIAID) Routh [E] (jennifer.routh@nih.gov) <jennifer.routh@nih.gov>; John Burklow (burklowj@od.nih.gov) <burklowj@od.nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Gretchen Michael (Gretchen.Michael@hhs.gov) <Gretchen.Michael@hhs.gov>; Elleen Kane (OS/ASPR/OEA) (Elleen.Kane@hhs.gov) <Elleen.Kane@hhs.gov>; Danko, Carol (OS/ASPR/IO) <Carol.Danko@hhs.gov>; Mia Heck (HHS/OASH) (Mia.Heck@hhs.gov) <Mia.Heck@hhs.gov>; Tara Broido (Tara.Broido@hhs.gov) <Tara.Broido@hhs.gov>; Jennifer Sherman (HHS/OASH) (Jennifer.Sherman@hhs.gov) <Jennifer.Sherman@hhs.gov>

Cc: Blakeman, Scott (OS/ASPA) <Scott.Blakeman@hhs.gov>; Brennan, Patrick (OS/ASPA) <Patrick.Brennan@hhs.gov>; Caputo, Michael (HHS/ASPA) <Michael.Caputo@hhs.gov>; Foster, Timothy (OS/ASPA) <Timothy.Foster@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>; Traverse, Brad (HHS/ASPA) <Brad.Traverse@hhs.gov>; Weber, Mark (HHS/ASPA) <Mark.Weber@hhs.gov>

Subject: RE: for clearances

Just a quick follow-up here to clarify on this: there's not been a change in the COVID-19

clearance process. Stuff still needs to be flagged for ASPA and/or approved by ASPA before going up to WH/OVP. The email below was simply to update you all on who at WH/OVP will need to receive the clearance emails when they go up to WH/OVP. The processes we've been following remain in place. Please call with any questions.

From: Murphy, Ryan (OS/ASPA)

Sent: Monday, May 11, 2020 12:42 PM

To: Lemar, Naweed (OS/ASPA) <Naweed.Lemar@hhs.gov>; Michael Robinson (<michael.robinson@hhs.gov> <michael.robinson@hhs.gov>; Simone Myrie (<Simone.Myrie@hhs.gov> <Simone.Myrie@hhs.gov>; Bradley, Tasha (OS/ASPA) <Tasha.Bradley@hhs.gov>; Formoso, Paula (HHS/ASPA) <Paula.Formoso@hhs.gov>; Daniels, Carla (HHS/ASPA) <Carla.Daniels@hhs.gov>; Felberbaum, Michael (FDA/OC) <Michael.Felberbaum@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Molly Block (<Molly.Block@fda.hhs.gov> <Molly.Block@fda.hhs.gov>; Kate Galatas (CDC/OD/OADC) (<kkg2@cdc.gov> <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oury, Rachael (CDC/OD) <QKC3@cdc.gov>; Courtney (NIH/NIAID) Billet [E] (<billetec@niaid.nih.gov> <billetec@niaid.nih.gov>; Jennifer (NIH/NIAID) Routh [E] (<jennifer.routh@nih.gov> <jennifer.routh@nih.gov>; John Burklow (<burklowj@od.nih.gov> <burklowj@od.nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Gretchen Michael (<Gretchen.Michael@hhs.gov> <Gretchen.Michael@hhs.gov>; Elleen Kane (OS/ASPR/OEA) (<Elleen.Kane@hhs.gov> <Elleen.Kane@hhs.gov>; Danko, Carol (OS/ASPR/IO) <Carol.Danko@hhs.gov>; Mia Heck (HHS/OASH) (<Mia.Heck@hhs.gov> <Mia.Heck@hhs.gov>; Tara Broido (<Tara.Broido@hhs.gov> <Tara.Broido@hhs.gov>; Jennifer Sherman (HHS/OASH) (<Jennifer.Sherman@hhs.gov> <Jennifer.Sherman@hhs.gov>
Cc: Blakeman, Scott (OS/ASPA) <Scott.Blakeman@hhs.gov>; Brennan, Patrick (OS/ASPA) <Patrick.Brennan@hhs.gov>; Caputo, Michael (HHS/ASPA) <Michael.Caputo@hhs.gov>; Foster, Timothy (OS/ASPA) <Timothy.Foster@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>; Traverse, Brad (HHS/ASPA) <Brad.Traverse@hhs.gov>; Weber, Mark (HHS/ASPA) <Mark.Weber@hhs.gov>

Subject: for clearances

Hey Folks – we thought it might be helpful to send an update to what folks at WH/OVP should receive clearance emails. Below reflects our understanding of who has been routinely receiving clearance items and/or who WH/OVP has often added to a chain for review. I've bucketed the lists below. Please let me know if you have any questions.

- Ryan

For material and print interview clearances –

Devin O'Malley (b) (6) @ovp.eop.gov)

Katie Miller (b) (6) ovp.eop.gov)

Hannah MacInnis (b) (6) @ovp.eop.gov)

Meghan Burris (b) (6) @who.eop.gov)

Brittany Yanick (b) (6) @who.eop.gov)

Tori Syrek (b) (6) @who.eop.gov)

Judd Deere (b) (6) @who.eop.gov)

For broadcast interview clearances –

Devin O'Malley

Katie Miller

Hannah MacInnis

Meghan Burris

Brittany Yanick

Tori Syrek

Judd Deere

Alexa Henning (b) (6) g@who.eop.gov)

Roma Daravi (b) (6) @who.eop.gov)

John Hortsman (b) (6) who.eop.gov)